Jepsen Peter
Peter Jepsen, Department of Hepatology and Gastroenterology, Aarhus University Hospital, DK-8000 Aarhus C, Denmark.
World J Gastroenterol. 2014 Jun 21;20(23):7223-30. doi: 10.3748/wjg.v20.i23.7223.
Cirrhosis patients' comorbidities are their other diseases than cirrhosis. Comorbidities are neither causes nor consequences of cirrhosis, but they can increase mortality and are therefore clinically important. They are also an important source of confounding in epidemiologic studies. Comorbidity scoring systems have been developed as tools to measure the cirrhosis patient's total burden of comorbidity, and they are useful in the clinic and for epidemiologic studies. The recently developed CirCom score is the only comorbidity scoring system developed specifically for cirrhosis patients, and it may be preferred over the older, generic, and more complex Charlson comorbidity index. Studies of individual comorbid diseases can provide insight into the interactions between cirrhosis and other diseases and thus into the pathophysiology of cirrhosis. This article reviews the literature on comorbidity in cirrhosis.
肝硬化患者的合并症是指除肝硬化之外的其他疾病。合并症既不是肝硬化的病因，也不是其后果，但它们会增加死亡率，因此具有临床重要性。它们也是流行病学研究中混杂因素的重要来源。合并症评分系统已被开发出来作为衡量肝硬化患者合并症总负担的工具，在临床和流行病学研究中都很有用。最近开发的CirCom评分是唯一专门为肝硬化患者开发的合并症评分系统，可能比旧的、通用的且更复杂的Charlson合并症指数更具优势。对个别合并症疾病的研究可以深入了解肝硬化与其他疾病之间的相互作用，从而深入了解肝硬化的病理生理学。本文综述了关于肝硬化合并症的文献。
